Posts tagged “Genomics”
The numbers continue to climb for North Carolina's life science sector, bringing new companies, high-paying jobs and opportunity statewide, according to a new report.
Ron Sederoff, an NC State forestry professor and pioneering molecular geneticist, has won the 2017 Marcus Wallenberg Foundation Prize, an international award for scientific achievements in fields important to forestry.
The new program, to be managed by NCBiotech, will support distinguished postdoctoral fellowships in North Carolina university research laboratories providing advanced scientific training in gene therapy-related research.
Metabolon, the RTP-based life science company focusing on the science of metabolomics, is expanding its management team with a new chief medical officer. The firm also promotes an exec to CFO.
Are you ready to explore baby's genome? UNC clinical geneticists are part of a national consortium of researchers studying the ins and outs of genome sequencing for newborn health screenings and beyond.
Some genetically engineered foods such as White Russet potatoes and Arctic apples that don't brown remain controversial. But not all food technology innovations discussed at the North Carolina Biotechnology Center's AgBiotech Summit 2016 earlier this month engender social fears.
Charlotte's entrepreneurial community is growing far beyond a traditional reliance on the Queen City's financial industry. An example is agbio statrtup Soymeds. This is the first in a series of exclusive interviews about Charlotte startups.
Durham-based Bioventus, a fast-growing global orthobiologics company, has launched its second U.S. product for injection to relieve knee pain for osteoarthritis (OA) sufferers.
In our latest wrapup of Triangle headlines from other publications, catch up on reports about the new Fortune 500 and what North Carolina firms made it as well as news about Time Warner Cable, Metabolon and an investigation into H-1B visas in Charlotte.
In today's Bulldog wrapup of technology and science news: The U.S. reportedly will OK a private space mission to Moon; analyst arrested for insider trading in Pfizer case; scientists propose making human DNA; and Nest's CEO is out.
Genetically manipulated food remains generally safe for humans and the environment, a high-powered science advisory board declared in a report Tuesday. The project was chaired by Fred Gould, a professor at North Carolina State University.
The North Carolina Biotechnology Center works across the state to grow companies and technologies that will help to heal, fuel and feed the world. As you can imagine, we hear a lot of great stories while doing this work. And nowhere are there more stories than in Durham.
Answered prayers? Recently blessed for its work by the Pope, Bamboo Therapeutics, a recently launched life sciences venture focusing on gene therapy to treat deadly childhood neurological disorders, has raised nearly $50 million from investors. CureDuchenne Ventures LLC, a venture philanthropy organization, is among the backers.
Britain's decision to allow researchers to edit the genes of human embryos -- not to create babies but to start unraveling the earliest stages of development -- is raising new questions about the ethics of this hot new technology.
A Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease. The team operates out of the Durham Innovation District.
Every year an estimated 3 to 5 million sharks are slaughtered for a precious omega-2 oil in their livers called squalene, a clear liquid, lighter than water, that helps them float. SynShark, which has operations in NC, wants to harvest squalene from the leaves of tobacco plants that have been genetically engineered to synthesize the oil.
Bret Kopelan's daughter Rafaella, now eight, was born without skin on her feet and had to have emergency care when her skin began to blister. She suffers from a rare disease that had no effective treatments currently because it doesn't affect enough people to make it commercially viable for most drug companies. So Kopelan is hopeful that a Durham company's treatment gets to market quickly and helps his daughter.